Gilead Sciences, Inc. (NASDAQ:GILD) Stake Reduced by Atwood & Palmer Inc.

Atwood & Palmer Inc. lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 345,067 shares of the biopharmaceutical company’s stock after selling 4,189 shares during the quarter. Gilead Sciences makes up approximately 2.7% of Atwood & Palmer Inc.’s portfolio, making the stock its 6th biggest position. Atwood & Palmer Inc.’s holdings in Gilead Sciences were worth $38,665,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $33,000. Annis Gardner Whiting Capital Advisors LLC boosted its holdings in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 216 shares in the last quarter. Morton Brown Family Wealth LLC purchased a new position in Gilead Sciences during the 4th quarter valued at $35,000. Whipplewood Advisors LLC bought a new position in Gilead Sciences in the 4th quarter worth $35,000. Finally, Synergy Investment Management LLC bought a new stake in shares of Gilead Sciences during the 4th quarter valued at about $40,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Wells Fargo & Company lifted their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Morgan Stanley raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Bank of America increased their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $110.55.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $113.00 on Tuesday. The firm has a market capitalization of $140.56 billion, a PE ratio of 305.41, a P/E/G ratio of 0.71 and a beta of 0.29. The company has a 50 day moving average price of $105.41 and a 200-day moving average price of $101.80. Gilead Sciences, Inc. has a 52 week low of $62.69 and a 52 week high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.32) EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.80%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s dividend payout ratio is 66.53%.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the transaction, the chief executive officer now directly owns 620,268 shares of the company’s stock, valued at $68,489,992.56. The trade was a 1.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider now directly owns 121,152 shares in the company, valued at $13,026,263.04. This represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 43,000 shares of company stock worth $4,630,310 in the last three months. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.